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Abstract
Background We established algorithms to predict the
prognosis of acute liver failure (ALF) patients through a
data-mining analysis, in order to improve the indication
criteria for liver transplantation.
Methods The subjects were 1,022 ALF patients seen
between 1998 and 2007 and enrolled in a nationwide survey.
Patients older than 65 years, and those who had undergone
liver transplantation and received blood products before the
onsetofhepaticencephalopathywereexcluded.Twodatasets
were used: patients seen between 1998 and 2003 (n=698),
whose data were used for the formation of the algorithm, and
those seen between 2004 and 2007 (n=324), whose data were
used for the validation of the algorithm. Data on a total of 73
items, at the onset of encephalopathy and 5 days later, were
collectedfrom371ofthe698patientsseenbetween1998and
2003, and their outcome was analyzed to establish decision
trees. The obtained algorithm was validated using the data of
160 of the 324 patients seen between 2004 and 2007.
Results The outcome of the patients at the onset of
encephalopathy was predicted through 5 items, and the
patients were classiﬁed into 6 categories with mortality
rates between 23% and89%. When the prognosis of the
patients in the categories with mortality rates greater than
50% was predicted as ‘‘death’’, the accuracy, sensitivity,
speciﬁcity, positive predictive value (PPV), and negative
predictive value (NPV) of the algorithm were 79, 78, 81,
83, and 75%, respectively. Similar high values were
obtained when the algorithm was employed in the patients
for validation. The outcome of the patients 5 days after the
onset of encephalopathy was predicted through 7 items,
and a similar high accuracy was found for both sets of
patients.
Conclusions Novel algorithms for predicting the out-
come of ALF patients may be useful to determine the
indication for liver transplantation.
Keywords Hepatic encephalopathy  Liver
transplantation  Fulminant hepatitis  Late-onset hepatic
failure
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Acute liver failure (ALF) is a clinical syndrome charac-
terized by hepatic encephalopathy and a bleeding tendency
due to the severe impairment of liver function caused by
massive or submassive liver necrosis. In Japan, patients
showing 40% or less of the standardized prothrombin time
value or INRs of 1.5 or more caused by severe liver
damage within 8 weeks of onset of the symptoms are
diagnosed as having ALF, where the liver function prior to
the current onset of liver damage was estimated to be
normal [1]. ALF is classiﬁed into the categories of ‘‘acute
liver failure without hepatic coma’’ and ‘‘acute liver failure
with hepatic coma,’’ depending on the severity of the
hepatic encephalopathy; the latter is further classiﬁed into 2
types, the ‘‘acute type’’ and the ‘‘subacute type’’, in which
grade II or more severe hepatic coma develops within
10 days and between 11 and 56 days, respectively, after
the onset of disease symptoms. Also, patients with less than
40% of the standardized prothrombin time value or INRs of
1.5 or more and grade II or more severe hepatic coma
occurring between 8 and 24 weeks of the onset of disease
symptoms are diagnosed as having late-onset hepatic fail-
ure (LOHF), as a disease related to ALF. ALF in Japan has
been typically regarded as fulminant hepatitis, for which
the diagnostic criteria were established by the Inuyama
Symposium held in 1981 [2]. Among patients with ALF,
those showing histological ﬁndings of hepatitis (charac-
terized by inﬂammatory lymphocyte inﬁltration), as well as
40% or less of the standardized prothrombin timeand grade
II or more severe hepatic encephalopathy, are diagnosed as
having ‘‘fulminant hepatitis’’, which is classiﬁed as acute
and subacute types in the same manner as ALF [2, 3]. Thus,
fulminant hepatitis is almost synonymous with ALF in the
United States and Europe as well as in Japan, except that
patients without histological evidence of hepatitis are
excluded from both disease conditions in Japan. Thus, ALF
caused by viral infections, autoimmune hepatitis, and drug
allergy-induced liver injury is included in the diagnosis of
fulminant hepatitis, while ALF caused by drug/chemical
intoxication (such as acetaminophen intoxication) micro-
circulatory disturbances, Wilson’s disease, acute fatty liver
of pregnancy, and Reye’s syndrome is excluded from that.
A history of chronic liver disease preceding the onset of
acute liver injury also precludes the diagnosis of fulminant
hepatitis and LOHF, while inactive hepatitis B virus (HBV)
carriers showing normal serum alanine aminotransferase
(ALT) values before acute exacerbation of hepatitis are
included in both these disease conditions.
According to a nationwide survey conducted by the
Intractable Liver Diseases Study Group of Japan consti-
tuted under the aegis of the Ministry of Health, Welfare
and Labour [4], artiﬁcial liver support with plasma
exchange and/or hemodiaﬁltration was performed in
almost all patients with fulminant hepatitis and LOHF
between 1998 and 2003. Also, about 70 and 60% of the
patients, respectively, received intravenous glucocorticoid
treatment and anticoagulant therapy with an antithrombin
III concentrate. Moreover, patients with HBV infection
have received antiviral therapy with lamivudine or ente-
cavir since 1998. Despite the use of these therapeutic
modalities, however, the outcome of the patients receiving
these treatments had not improved; the survival rates of
patients with the acute and subacute types of fulminant
hepatitis not treated with liver transplantation were 54 and
24%, respectively, , and in those with LOHF not treated
with liver transplantation the survival rate was 12% [4]. In
contrast, the outcome of the patients receiving liver trans-
plantation was excellent, with the survival rate being 78%
among those with fulminant hepatitis and 75% among
those with LOHF, suggesting that liver transplantation is
the optimal therapeutic strategy for the rescue of patients
with ALF, irrespective of the disease types in Japan.
The indications for liver transplantation in patients with
ALF are currently determined according to the guideline
published by the Acute Liver Failure Study Group of Japan
in 1996 [5, 6]. The predictive accuracy, however,
decreased when the guideline was adopted for patients seen
between 1998 and 2003; the accuracy values in the patients
not receiving liver transplantation were 67 and 78% among
those with the acute and subacute types of fulminant hep-
atitis, respectively, and the speciﬁcity of the guideline was
extremely low especially in patients with the subacute type
of fulminant hepatitis [6]. Thus, the guideline to determine
the indication for liver transplantation in ALF patients in
Japan needs to be updated.
Recently, we performed a cluster analysis of the patients
with fulminant hepatitis and LOHF seen between 1998 and
2007 to evaluate the validity of the classiﬁcation of ALF in
Japan [7]. We adopted the self-organizing map (SOM), one
of the data-mining methods introduced by Kohonen as an
artiﬁcial neural network [8], which has been shown to be
suitable for analyses of complex multidimensional rela-
tionships in various medical science ﬁelds [9–15]. Conse-
quently, we found that ALF patients could be classiﬁed into
three clusters independent of the interval between the onset
of disease symptoms and the development of hepatic
encephalopathy, and the outcome of the patients differed
markedly among the clusters [7]. These observations
prompted us to postulate that data-mining methods may be
useful to revise the above-mentioned guideline.
We report on algorithms to predict the outcome of ALF
patients under intensive medical care without liver trans-
plantation; these algorithms were established based on the
data-mining analysis using decision trees. The algorithms
were constructed using the data from ALF patients without
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123liver transplantation, because there may have been many
patients among those receiving liver transplantation who
could have been rescued by intensive medical care.
Patients and methods
Patients
The subjects of this study were 1,022 patients with ALF
who were enrolled in the nationwide survey of fulminant
hepatitis and LOHF conducted by the Intractable Hepato-
Biliary Disease Study Group of Japan between 1999 and
2008 (formerly the Intractable Liver Diseases Study Group
of Japan, before 2003). All of the patients showed grade II
or more severe hepatic encephalopathy and prothrombin
times of less than 40% of the standardized value and were
admitted to 610 hospitals specializing in hepatology in
Japan between 1998 and 2007. Patients without histologi-
cal evidence of hepatitis, such as those with hepatitis due to
drug-toxicity, circulatory disturbance, and metabolic dis-
eases, were excluded from the analysis. The interval
between the onset of the hepatitis symptoms and the
development of encephalopathy was 10 days or less in 472
patients (group-A; acute type of fulminant hepatitis),
between 11 and 56 days in 468 patients (group-B; subacute
type of fulminant hepatitis), and more than 56 days in 82
patients (group-C; LOHF). The patients were classiﬁed into
two data sets; 698 patients (316, 318, and 64 in group-A,
group-B, and group-C, respectively) seen between 1998
and 2003, and 324 patients (156, 150, and 18, respectively,
in each group) seen between 2004 and 2007. The former
data set was used for the formation of the algorithms to
predict the outcome of the patients and the latter data set
was used for the validation of the established algorithms.
The clinical features of all patients were obtained until
either of the following time-points: they died in hospital, or
received liver transplantation, or were discharged follow-
ing improvement of liver function; the outcomes of the
patients were expressed as ‘‘dead’’, ‘‘transplanted’’, and
‘‘rescued’’, respectively. Missing data were managed
through available-case analysis, in which all relevant data
were used.
The etiology of ALF was determined based on the
deﬁnition proposed by the Intractable Liver Diseases Study
Group of Japan constituted under the aegis of the Ministry
of Health, Welfare and Labour [1, 4]. Criteria for com-
plications were deﬁned as follows: Infection; (1) manifes-
tation of organic symptoms and/or imaging ﬁndings, (2)
body temperature of 38C or more, (3) white blood cell
counts of 10,000 cells/mm
3 or more, (4) positive for
causative bacteria in organs suspicious of infection and/or
increase of white blood cell counts in body ﬂuid. Patients
were diagnosed as having infection when two or more of
these criteria were present. Brain edema; (1) typical ﬁnd-
ings on computed tomography (CT) images, or (2) intra-
cranial pressure of 25 mmHg or more. Gastrointestinal
bleeding; (1) hematemesis and/or drainage of blood from a
catheter in the upper gastrointestinal tract, (2) tarry stool or
melena, (3) endoscopic ﬁndings of bleeding. Patients were
diagnosed as having gastrointestinal bleeding when one or
more of these criteria were present. Renal failure; (1) urine
volume output of 400 mL or less per day, or (2) serum
creatinine levels of 2.0 mg/dL or higher. Disseminated
intravascular coagulation (DIC); patients were diagnosed
as having DIC when the score on the scoring system for
DIC revised by the Japanese Association for Acute Medi-
cine (JAAM) [16] was four or more. Heart failure; (1)
chest X-ray showing an enlarged cardiac silhouette, (2)
chest X-ray showing pulmonary congestion, (3) an ejection
fraction of 40% or less. Patients were diagnosed as having
heart failure when two or more of these criteria were
present. Atrophy of the liver was assessed by each practi-
tioner subjectively based on imaging through ultrasound
and/or CT scan examinations.
The demographic and clinical features, the therapies
undertaken, and the consequent outcomes of the patients
are shown in the various sections of Table 1. Of the total
study population seen between 1998 and 2007, 40.2% had
underlying diseases such as metabolic syndrome, and most
of such patients were on daily medications. The etiology of
hepatitis was viral infection in 69.3, 31.2, and 17.1% of the
patients in group-A, group-B, and group-C, respectively. In
most cases, the causative virus was hepatitis B virus
(HBV); transient infection was predominant in the patients
in group-A, whereas inactive carriers showing acute
exacerbation of hepatitis predominated in group-B. The
etiology was indeterminate in 41.5 and 47.6% of the
patients in group-B and group-C, respectively. Autoim-
mune hepatitis and drug-induced liver injury were found in
12.0 and 13.0%, respectively, of the patients in group-B,
and in 17.1 and 15.9%, respectively, of those in group-C.
The survival rates of the 811 patients who were treated
conservatively without liver transplantation were 53.4,
24.5, and 12.1%, respectively, in group-A, group-B, and
group-C patients. The remaining 211 patients (20.6%)
underwent liver transplantation, and the survival rates were
56.4, 39.7, and 25.6%, respectively, in the patients in
group-A, group-B, and group-C.
The demographic and clinical features in the patients
seen between 1998 and 2003 and those seen between 2004
and 2007 were similar, except for the following items
(Table 1a): the ages of the patients seen between 2004 and
2007 were signiﬁcantly higher than the ages in those seen
between 1998 and 2003 irrespective of the groups to which
they belonged . On the other hand, the percentage of HBV
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123Table 1 Demographic and clinical features of acute liver failure patients in Japan seen between 1998 and 2003 and those seen between 2004 and
2007
(a) Demographic features and the etiology of acute liver failure
1998–2003 Total (n = 698) Group-A
a (n = 316) Group-B (n = 318) Group-C (n = 64)
Male:female (:unknown)
b 346:351 (:1) 167:148 (:1) 152:166 27:37
Age (years)
c 47.0 ± 16.8
 45.1 ± 16.6
 47.8 ± 17.1
 51.9 ± 15.0

HBV carrier
d 14.1 (93/658)* 12.7 (37/291)* 17.4 (53/305) 4.8 (3/62)
Underlying diseases
d, e 38.5 (265/689) 32.7 (102/312) 41.5 (130/313) 51.6 (33/64)
History of medication
d 42.0 (282/672)* 36.6 (112/306)* 45.7 (139/304)* 50.0 (31/62)
Etiology
d
Viral infection 48.0 (335) 71.2 (225) 31.8 (101) 14.1 (9)
HAV 6.4 (45)
# 12.0 (38) 1.9 (6) 1.6 (1)
HBV 38.8 (271) 56.6 (179) 27.0 (86) 9.4 (6)
Transient infection 23.2 (162) 41.8 (132) 8.8 (28) 3.1 (2)
Carrier 13.5 (94) 12.0 (38) 16.7 (53) 4.7 (3)
Undetermined 2.1 (15)
# 2.8 (9)
# 1.6 (5) 1.6 (1)
HCV 1.4 (10) 1.6 (5) 1.3 (4) 1.6 (1)
HEV 0.4 (3) 0 (0)
# 0.9 (3) 0 (0)
Other virus 0.9 (6) 0.9 (3) 0.6 (2) 1.6 (1)
Autoimmune hepatitis 6.9 (48) 1.6 (5) 10.7 (34) 14.1 (9)
Drug allergy-induced 9.3 (65)
# 6.0 (19)
# 11.3 (36) 15.6 (10)
Indeterminate 32.8 (229) 18.7 (59) 42.8 (136) 53.1 (34)
Insufﬁcient examinations
f 3.0 (21)
# 2.5 (8) 3.5 (11) 3.1 (2)
2004–2007 Total (n = 324) Group-A
a (n = 156) Group-B (n = 150) Group-C (n = 18)
Male:female
b 152:172 82:74 64:86 6:12
Age (years)
c 51.1 ± 16.1 48.6 ± 15.5 52.7 ± 16.5 60.3 ± 11.5
HBV carrier
d 11.7 (33/282) 9.5 (12/126) 13.7 (19/139) 11.8 (2/17)
Underlying diseases
d, e 44.0 (139/316) 39.7 (60/151) 47.6 (70/147) 50.0 (9/18)
History of medication
d 60.3 (184/305) 51.7 (75/145) 66.9 (95/142) 77.8 (14/18)
Etiology
d
Viral infection 46.9 (152) 65.4 (102) 30.0 (45) 33.3 (6)
HAV 3.1 (10) 6.4 (10) 0.0 (0) 0.0 (0)
HBV 41.0 (133) 56.4 (88) 26.7 (40) 27.8 (5)
Transient infection 21.9 (71) 38.5 (60) 6.7 (10) 5.6 (1)
Carrier 12.3 (40) 6.4 (10) 18.0 (27) 16.7 (3)
Undetermined 6.8 (22) 11.5 (18) 2.0 (3) 5.6 (1)
HCV 0.9 (3) 0.6 (1) 1.3 (2) 0.0 (0)
HEV 1.2 (4) 1.3 (2) 1.3 (2) 0.0 (0)
Other virus 0.6 (2) 0.6 (1) 0.7 (1) 0.0 (0)
Autoimmune hepatitis 9.9 (32) 3.2 (5) 14.7 (22) 27.8 (5)
Drug allergy-induced 14.5 (47) 12.2 (19) 16.7 (25) 16.7 (3)
Indeterminate 27.8 (90) 17.3 (27) 38.7 (58) 27.8 (5)
Insufﬁcient examinations
f 0.9 (3) 1.9 (3) 0.0 (0) 0.0 (0)
(b) Complications of acute liver failure
g
1998–2003 Total (n = 698) Group-A
a (n = 316) Group-B (n = 318) Group-C (n = 64)
Infection 39.1 (247/632) 35.0 (100/286) 40.8 (117/287) 50.8 (30/59)
Brain edema 31.0 (173/558)* 35.3 (91/258)* 29.0 (73/252)* 18.8 (9/48)
Gastrointestinal bleeding 20.1 (134/668) 22.2 (67/302)* 16.7 (51/305) 26.2 (16/61)
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(b) Complications of acute liver failure
g
1998–2003 Total (n = 698) Group-A
a (n = 316) Group-B (n = 318) Group-C (n = 64)
Renal failure 36.5 (249/682) 41.5 (129/311)* 29.9 (92/308) 44.4 (28/63)
DIC 41.5 (271/653) 43.4 (129/297)* 41.3 (124/300) 33.9 (19/56)
Congestive heart failure 10.5 (70/664)* 11.2 (34/303) 9.6 (29/301)* 11.7 (7/60)
2004–2007 Total (n = 324) Group-A
a (n = 156) Group-B (n = 150) Group-C (n = 18)
Infection 35.7 (109/305) 33.8 (49/145) 35.9 (51/142) 50.0 (9/18)
Brain edema 16.7 (47/282) 20.1 (28/139) 11.7 (15/128) 26.7 (4/15)
Gastrointestinal bleeding 15.4 (48/312) 12.5 (19/152) 17.4 (25/144) 25.0 (4/16)
Renal failure 35.4 (113/319) 35.7 (55/154) 35.4 (52/147) 33.3 (6/18)
DIC 35.1 (108/308) 30.6 (45/147) 37.1 (53/143) 55.6 (10/18)
Congestive heart failure 7.6 (23/303) 8.7 (13/150) 5.8 (8/137) 12.5 (2/16)
(c) Therapeutic strategies undertaken following the onset of hepatic encephalopathy
g
1998–2003 Total (n = 698) Group-A
a (n = 316) Group-B (n = 318) Group-C (n = 64)
Glucocorticoids 67.6 (470/695) 60.5 (190/314) 76.0 (241/317) 75.0 (48/64)
Glucagon/insulin 43.2 (300/694)* 37.6 (118/314)* 47.5 (150/316)* 50.0 (32/64)*
BCAA-rich solution 32.9 (227/689)* 27.6 (86/312) 35.8 (112/313)* 45.3 (29/64)
Plasma exchange 91.1 (634/696) 90.1 (283/314) 93.4 (297/318) 84.4 (54/64)
Hemodiaﬁltration 74.7 (518/693) 75.2 (236/314) 77.2 (244/316) 60.3 (38/63)
Prostaglandin E1 23.2 (160/691)* 19.4 (61/314)* 25.8 (81/314)* 28.6 (18/63)*
Cyclosporin A 13.9 (96/691)* 11.1 (35/314) 15.9 (50/314) 17.5 (11/63)
Interferon 19.5 (135/691)* 22.0 (69/314)* 19.7 (62/314)* 6.3 (4/63)
Nucleoside analog 23.9 (164/687)* 30.9 (96/311)* 20.4 (64/314)* 6.5 (4/62)*
Anticoagulation therapy 59.6 (413/693)* 57.3 (180/314)* 60.1 (190/316) 68.3 (43/63)*
Liver transplantation 20.3 (142/698) 14.6 (46/316) 26.4 (84/318)* 18.8 (12/64)
2004–2007 Total (n = 324) Group-A
a (n = 156) Group-B (n = 150) Group-C (n = 18)
Glucocorticoids 71.8 (232/323) 66.7 (104/156) 75.8 (113/149) 83.3 (15/18)
Glucagon/insulin 15.5 (50/323) 16.7 (26/156) 14.1 (21/149) 16.7 (3/18)
BCAA-rich solution 23.7 (76/321) 18.2 (28/154) 26.2 (39/149) 50.0 (9/18)
Plasma exchange 90.7 (293/323) 92.3 (144/156) 91.3 (136/149) 72.2 (13/18)
Hemodiaﬁltration 69.9 (225/322) 69.7 (108/155) 73.8 (110/149) 38.9 (7/18)
Prostaglandin E1 7.4 (24/323) 7.7 (12/156) 7.4 (11/149) 5.6 (1/18)
Cyclosporin A 9.0 (29/323) 6.4 (10/156) 11.4 (17/149) 11.1 (2/18)
Interferon 13.3 (43/323) 14.7 (23/156) 12.1 (18/149) 11.1 (2/18)
Nucleoside analog 39.1 (126/322) 51.6 (80/155) 27.5 (41/149) 27.8 (5/18)
Anticoagulation therapy 45.5 (147/323) 39.1 (61/156) 54.4 (81/149) 27.8 (5/18)
Liver transplantation 21.3 (69/324) 12.8 (20/156) 30.0 (45/150) 22.2 (4/18)
(d) The outcome of the patients
g
1998–2003 Total (n = 698) Group-A
a (n = 316) Group-B (n = 318) Group-C (n = 64)
Survival rate 45.6 (318/698) 56.3 (178/316) 39.3 (125/318) 23.4 (15/64)
Treated without liver transplantation 37.4 (208/556) 53.7 (145/270) 24.4 (57/234) 11.5 (6/52)
Treated with liver transplantation 77.5 (110/142) 71.7 (33/46) 81.0 (68/84) 75.0 (9/12)
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1998 and 2003 compared to the percentage in those seen
between 2004 and 2007. In contrast, the percentages of
patients with previous medication in group-A and group-B
were greater in those seen between 2004 and 2007 than in
those seen between 1998 and 2003. There were also dif-
ferences in the incidence of brain edema and congestive
heart failure between patients seen between 1998 and 2003
and those seen between 2004 and 2007 (Table 1b). Also,
the percentages of patients who received therapies such as
glucagon and insulin infusion, administration of branched-
chain-rich amino acid, prostaglandin E1, interferon, and
nucleoside analogs for HBV, and anticoagulant therapies,
were different between the two data sets (Table 1c).
However, the survival rates of patients both with and
without liver transplantation were equivalent in the two
data sets (Table 1d).
The following patients were excluded from both data
sets: (1) patients older than 65 years; (2) those who had
undergone liver transplantation; and (3) those who had
received blood product administration before the onset of
hepatic encephalopathy. Patients aged more than 65 years
were excluded from the analysis because the Act on Organ
Transplantation (Law number: Act No. 104 of 1997) rec-
ommends that liver transplantation recipients should be
younger than 60 years, and in general, in Japan, liver
transplantation has been done in recipients aged 65 years
or less. Consequently, the data of 371 patients (male 196,
female 175) aged between 2 and 65 years (mean ± SD
44.1 ± 14.2) seen between 1998 and 2003 were used for
the formation of the algorithms. The disease types of these
patients were group-A, group-B, and group-C in 206, 140,
and 25 patients, respectively. Validation of the established
algorithms was performed in 160 patients (male 81, female
79), aged between 17 and 65 years (47.5 ± 11.9), seen
between 2004 and 2007 (98, 56, and 6 patients in group-A,
group-B, and group-C, respectively). The algorithms were
also employed for the 211 patients who had received liver
transplantation between 1998 and 2007, comprising 80
male and 131 female patients aged between 7 and 70 years
(39.6 ± 15.6), with 66, 129, and 16 patients belonging to
group-A, group-B, and group-C, respectively.
Formation of the algorithms through decision tree
analysis
Two types of algorithms were formed using the different
data sets; one for the prediction of the patients’ outcome at
the onset of hepatic encephalopathy of grade II or more
(day 0), and the other for the prediction 5 days later (day
5). Data on a total of 62 items, including: (1) the demo-
graphic features of the patients, (2) clinical features and
laboratory and imaging data at the onset of hepatic
encephalopathy, and (3) the therapies received until the
development of hepatic encephalopathy, were collected
from 371 patients seen between 1998 and 2003 (Table 2),
and used for the formation of the algorithm predicting the
patients’ outcome on day 0. Data on a total of 73 items,
including 62 items for the algorithm predicting the
patients’ outcome on day 0, and clinical features, labora-
tory and imaging data, and the therapies received at 5 days
after the onset of hepatic encephalopathy, collected from
the same patients, were used for the formation of the
algorithm predicting the patients’ outcome on day 5. Items
Table 1 continued
2004–2007 Total (n = 324) Group-A
a (n = 156) Group-B (n = 150) Group-C (n = 18)
Survival rate 47.8 (155/324) 56.4 (88/156) 40.7 (61/150) 33.3 (6/18)
Treated without liver transplantation 39.2 (100/255) 52.9 (72/136) 24.8 (26/105) 14.3 (2/14)
Treated with liver Transplantation 79.7 (55/69) 80.0 (16/20) 77.8 (35/45) 100.0 (4/4)
HBV hepatitis B virus, HAV hepatitis A virus, HCV hepatitis C virus, HEV hepatitis E virus, BCAA branched-chain amino acid, DIC disseminated
intravascular coagulation
a The interval between the onset of the hepatitis symptoms and the onset of grade II or more severe hepatic encephalopathy was 10 days or less
(group-A), between 11 and 56 days (group-B), and more than 56 days (group-C)
b Number of patients
c Mean ± SD
d The values are the percentages of patients (%), and the values in parentheses represent the numbers of patients for the calculation of the
percentage
e Diseases such as metabolic syndrome, malignancy, and psychiatric disorders
f The etiology was unknown because of insufﬁcient examinations
g The values are the percentages of patients (%), and the values in parentheses represent the numbers of patients for calculation of the percentage
 p\0.05 versus 2004–2007 by Student’s t-test
* p\0.05 versus 2004–2007 by the v
2 test
# p\0.05 versus 2004–2007 by the v
2 test and analysis of residuals in cross tabulation
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(a) Items for construction of the algorithm for the patients at the onset of hepatic encephalopathy (day 0)
The types of hepatitis: acute and subacute types of fulminant hepatitis and LOHF
Outcomes: survived and died among patients treated conservatively without liver transplantation and the patients who underwent
transplantation
Gender: male and female
Age (years, continuous variable)
Complications preceding acute liver failure: diseases different from liver diseases such as metabolic syndrome, psychiatric diseases, and
malignancies
HBV carrier
Past medical history: operations, blood infusions, alcohol intake, and medications
Family history: liver diseases
Etiology of hepatitis: viral infection [HAV, HBV (transient infection, carrier, undetermined), HCV, HEV, other virus], autoimmune
hepatitis, drug-induced, indeterminate, and unknown due to insufﬁcient examinations
Interval between the onset of the hepatitis symptoms and the subsequent events (days, continuous variables): onset of jaundice and grade II
or more severe hepatic encephalopathy
Interval between the onset of jaundice and the subsequent events (days, continuous variables): onset of hepatic encephalopathy of grade II or
more
Symptoms at the onset of grade II or more severe hepatic encephalopathy: fever, jaundice, ascites, edema, ﬂapping tremor, halitosis, loss of
liver dullness, convulsion, tachycardia, and hyperventilation
Laboratory data at the onset of grade II or more severe hepatic encephalopathy (continuous variables): the grading of the encephalopathy,
peripheral counts of WBC and platelets, prothrombin time, hepaplastin test, plasma concentrations of antithrombin III and ammonia, serum
concentrations of AST, ALT, total albumin, bilirubin, AFP, and HGF, the serum concentration ratios of direct to total bilirubin, molar ratio
of BCAA to tyrosine (BTR), and Fischer ratio
Atrophy of the liver at the onset of grade II or more severe hepatic encephalopathy
Complications of acute liver failure at the onset of grade II or more severe hepatic encephalopathy: bacterial and fungal infections,
gastrointestinal bleeding, renal failure, cardiac failure, disseminated intravascular coagulation, other complications
Number of complications at the onset of grade II or more severe hepatic encephalopathy (continuous variables)
The therapies received: plasma exchange, hemodiaﬁltration, glucocorticoids, glucagon and insulin, prostaglandin E1, interferon, lamivudine
or entecavir, cyclosporin A, anticoagulants, and fresh-frozen plasma
(b) Items for construction of the algorithm for the patients at 5 days after the onset of hepatic encephalopathy (day 5)
The types of hepatitis: acute and subacute types of fulminant hepatitis and LOHF
Outcomes: survived and died among patients treated conservatively without liver transplantation and the patients who underwent
transplantation
Gender: male and female
Age (years, continuous variable)
Complications preceding acute liver failure: diseases different from liver diseases such as metabolic syndrome, psychiatric diseases, and
malignancies
HBV carrier
Past medical history: operations, blood infusions, alcohol intake, and medications
Family history: liver diseases
Etiology of hepatitis: viral infection [HAV, HBV (transient infection, carrier, undetermined), HCV, HEV, other virus], autoimmune
hepatitis, drug-induced, indeterminate, and unknown due to insufﬁcient examinations
Interval between the onset of the hepatitis symptoms and the subsequent events (days, continuous variables): onset of jaundice and grade II
or more severe hepatic encephalopathy
Interval between the onset of jaundice and the subsequent events (days, continuous variables): onset of hepatic encephalopathy of grade II or
more
Symptoms at the onset of grade II or more severe hepatic encephalopathy: fever, jaundice, ascites, edema, ﬂapping tremor, halitosis, loss of
liver dullness, convulsion, tachycardia, and hyperventilation
Laboratory data at the onset of grade II or more severe hepatic encephalopathy (continuous variables): the grading of the encephalopathy,
peripheral counts of WBC and platelets, prothrombin time, hepaplastin test, plasma concentrations of antithrombin III and ammonia, serum
concentrations of AST, ALT, total albumin, bilirubin, AFP, and HGF, the serum concentration ratios of direct to total bilirubin, molar ratio
of BCAA to tyrosine (BTR), and Fischer ratio
Symptoms and laboratory data 5 days after the onset of encephalopathy (continuous variables): the grading of the encephalopathy,
prothrombin time
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123suchasage,bodyweight,andbiochemicaldatawereanalyzed
ascontinuousvariables,whilethosesuchasgender,outcomes,
and complications were analyzed as nominal variables.
The decision tree analysis was performed using Intelli-
gent Miner software (IBM, Armonk, New York, USA),
which can automatically search a data set to ﬁnd the
optimal classiﬁcation variables leading to the building of a
decision tree algorithm [15]. Brieﬂy, all items derived from
the patients were evaluated to determine which variables
and cutoff points might produce the most signiﬁcant divi-
sion into two subgroups showing mortality divergent from
each other. Then the same analytic procedures were
applied to all newly deﬁned subgroups. These procedures
were repeated and were terminated when either no addi-
tional signiﬁcant variables were detected or when the
sample size decreased to less than 20.
Evaluation of the established algorithms
The usefulness of the established algorithms was assessed
through the following evaluations: (1) comparison of the
mortality rates in patients belonging to each category to
observe differences between patients used for the forma-
tion and those used for the validation of the algorithms; (2)
the predictive accuracies, sensitivity, speciﬁcity, and
positive and negative predictive values (PPV and NPV)
among patients for both the formation and the validation of
the algorithms, calculated based on the postulation that the
outcome of the patients in the categories with mortality
rates greater than 50% was predicted as ‘‘death’’; and (3)
the distribution of the patients in each category, when the
data of the patients receiving liver transplantation were
applied for the algorithms.
In each evaluation, data on the totals of 62 and 73 items,
respectively, were selected for the algorithm at the onset of
hepatic encephalopathy and that at 5 days after the devel-
opment of encephalopathy, in a similar manner to the
selection of data for the formation of the algorithms.
Statistical analysis
Statistical testing was performed using SPSS version 15.0J
(SPSS, Tokyo, Japan). Results are expressed as means ±
SD. Continuous variables were compared using Student’s
t-test. Categorical data were compared using the v
2 test and
analysis of residuals in cross tabulation.
Results
Algorithms to predict the outcome of patients with ALF
based on decision tree analysis
Three hundred and seventy-one patients with ALF were
classiﬁed through 5 items into 6 categories on the decision
tree based on the data set obtained at the onset of hepatic
encephalopathy (day 0) (Fig. 1). The mortality rate of
patients with a serum bilirubin concentration of greater
than 17.9 mg/dL was 89% (category-1A: n = 91). Two
hundred and eighty patients with bilirubin concentrations
of less than 17.9 mg/dL were divided into 2 groups
according to peripheral blood platelet counts and further
divided into 6 category groups according to age, the
presence of ascites, and the disease etiology. The mortality
rate of patients showing peripheral blood platelet counts of
less than 10.2 9 10
4/mm
3 with ascites was 80% (category-
1B: n = 49). In contrast, 61 patients with peripheral blood
platelet counts of less than 10.2 9 10
4/mm
3 without ascites
were divided into 2 groups according to the disease etiol-
ogy; the mortality rate of patients with disease due to
hepatitis A virus (HAV) and hepatitis E virus (HEV)
infection and drug-allergy induced hepatitis, HBV carriers
showing acute hepatitis exacerbation, and those with
indeterminate etiology was 23% (category-1C: n = 31),
whereas the mortality rate of those with other etiologies
was 67% (category-1D: n = 30). The remaining 170
patients showing platelet counts of 10.2 9 10
4/mm
3 or
Table 2 continued
Atrophy of the liver at the onset of grade II or more severe hepatic encephalopathy and 5 days later Complications of acute liver failure at
the onset of grade II or more severe hepatic encephalopathy: Bacterial and fungal infections, gastrointestinal bleeding, renal failure, cardiac
failure, disseminated intravascular coagulation, other complications
Number of complications at the onset of grade II or more severe hepatic encephalopathy and 5 days later (continuous variables)
Complications of acute liver failure 5 days after the onset of encephalopathy: bacterial and fungal infections, gastrointestinal bleeding, renal
failure, cardiac failure, disseminated intravascular coagulation, other complications
Number of complications 5 days after the onset of encephalopathy (continuous variables)
The therapies received: plasma exchange, hemodiaﬁltration, glucocorticoids, glucagon and insulin, prostaglandin E1, interferon, lamivudine
or entecavir, cyclosporin A, anticoagulants, fresh-frozen plasma, and liver transplantation
LOHF late-onset hepatic failure, HAV hepatitis A virus, HBV hepatitis B virus, HCV hepatitis C virus, HEV hepatitis E virus WBC white blood
cell count, AST aspartate aminotransferase, ALT alanine aminotransferase, AFP alpha-fetoprotein, HGF hepatocyte growth factor, BCAA
branched-chain amino acids
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123more were divided into 2 groups according to the different
classiﬁcation criteria of disease etiology; the mortality rates
of HBV carriers showing acute hepatitis exacerbation and
patients with autoimmune hepatitis were 31% (category-
1E: n = 13) if the patient age was less than 39 years and
88% (category-1F: n = 17) if the age was 39 years old or
more, whereas the mortality rate of those with disease due
to other etiologies was 25% (category-1G: n = 140).
Based on the data set obtained 5 days after the onset of
hepatic encephalopathy (day 5), ALF patients were classiﬁed
through 7 items into 8 categories (Fig. 2). First, the patients
were divided into 2 groups according to prothrombin time at
5 days after the development of encephalopathy. One hun-
dred and ninety-two patients showing a prothrombin time of
less than 39.5% of the standardized value were further clas-
siﬁed through the presence of brain edema, liver atrophy, and
cardiac failure at 5 days after the onset of encephalopathy.
The mortality rate of patients with brain edema was 93%
(category-2A: n = 87), but those without brain edema
showed mortality rates of 80% (category-2B: n = 66), 16%
(category-2C: n = 31), and 100% (category-2D: n = 8),
respectively, when liver atrophy was present, both liver
atrophy and cardiac failure were absent, and cardiac failure
was present despite the absence of liver atrophy. In contrast,
179patientsshowingaprothrombintimeof39.5%ormoreof
the standardized value were classiﬁed by the serum bilirubin
concentration. The mortality rate of the patients showing
serum bilirubin concentrations of 17.45 mg/dL or more was
76% (category-2E: n = 33), whereas those with a serum
bilirubinconcentrationoflessthan17.45 mg/dLwere further
classiﬁed based on the presence of renal failure both at the
onset of hepatic encephalopathy and 5 days later. The mor-
tality rate of the patients without renal failure at 5 days after
the onset of the encephalopathy was 11% (category-2F:
n = 109). In contrast, the mortality rates of those with renal
failure at 5 days were 30% (category-2G: n = 27) and 90%
(category-2H: n = 10), respectively, depending on the
presence and absence of renal failure at the onset of the
encephalopathy.
As shown in Table 3, the predictive accuracies assessed
in patients for the establishment of the algorithms were
79% at the onset of hepatic encephalopathy and 84% at
5 days after the onset of encephalopathy, when the esti-
mated prognosis of patients classiﬁed in categories-1A,
-1B, -1D, and -1F and categories-2A, -2B, -2D, -2E, and
-2H was determined as ‘‘death’’. The sensitivity, speciﬁc-
ity, PPV, and NPV were 78, 81, 83, and 75%, respectively,
at the onset of the encephalopathy, and 83, 85, 87, and
81%, respectively, at 5 days later.
Validation of the established algorithms
One hundred and sixty patients with ALF, seen between
2004 and 2007, were classiﬁed into 7 categories through
170 201
81          10
160 120
39      10
66 44
Etiology: HAV, HEV
HBV carriers
Drug allergy-induced
Indeterminate
27
34
Etiology: HBV carriers
Autoimmune
Insufficient Examinations
HBV-undetermined 116
54
19
11
Age 39 y.o.
35     105
[25%]
1G
7       24
[22.6%]
20      10
[66.7%]
15        2
[88.2%] [30.8%]
4        9 1E 1D 1C 1F
Total Bilirubin-day 0 17.9 mg/dL
NO YES
NO YES
[89.0%]
NO
1A 
NO YES
YES
[54.1%] Platelet 10.19x104
[79.6%] NO
NO
YES
YES
1B
Ascites
Died
Survived
(n=371)
Fig. 1 The decision tree
algorithm for outcome
prediction at the onset of grade
II or more severe hepatic
encephalopathy (day 0). HBV
hepatitis B virus, HAV hepatitis
A virus, HEV hepatitis E virus
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123the analysis using the data set at the onset of hepatic
encephalopathy, and 8 categories using the data set at
5 days after the onset of encephalopathy. The number of
patients who died and the mortality rates of the patients in
each category are shown in Table 4. The distribution of the
patients and the mortality rates in each category were
almost equivalent to those in the patients used for the
formation of the algorithms both at the onset of hepatic
encephalopathy and 5 days later, except for category-2C.
The mortality rate in patients classiﬁed as category-2C was
16.1% in patients used for the formation of the algorithm,
while the rate was 91.7% in those used for the validation
(Table 4b).
The predictive accuracies assessed in patients for vali-
dation of the algorithms were 71 and 73%, respectively, at
the onset of hepatic encephalopathy and 5 days later,
similar to ﬁndings in the patients used for the formation of
the algorithms (Table 3). The sensitivity, speciﬁcity, PPV,
and NPV were 75, 67, 71, and 72%, respectively, at the
onset of the encephalopathy, and 64, 82, 78, and 70%,
respectively, at 5 days after the onset of encephalopathy.
Application of the algorithms for ALF patients
receiving liver transplantation
When the data from the 211 patients who had received liver
transplantation were applied for the established algorithms
at the onset of hepatic encephalopathy, 141 patients
(66.8%) were classiﬁed as category-1A, category-1B, cat-
egory-1D, or category-1F, in which categories the
[54.1%]
NO
170 201
YES
YES                NO
45
147
NO           YES [75.8%]
66 39
29
122
54
125
[93.1%]
25       8 81         6 2A 2E
NO              YES
NO YES
NO YES [80.3%]
13 26 53      13
[16.1%]
5       26
[100%]
8
[90%] [29.6%]
8        19
12      97
[11%]
9        1 2H 2G
NO YES
2F 20
17
2B
2C 2D
Cerebral  Edema-day 5
Prothrombin Time-day 5 39.5%
Total Bilirubin-day 0 17.45 mg/dL
Renal Failure-day 5 Liver Atrophy-day 5
Heart Failure-day 0
(n=371) Died
Survived
Renal Failure-day 0
Fig. 2 The decision tree
algorithm for outcome
prediction at 5 days after the
onset of grade II or more severe
hepatic encephalopathy (day 5)
Table 3 The accuracy of the decision tree algorithms to predict the
prognostic outcome of acute liver failure patients at the onset of
hepatic encephalopathy and 5 days later
At the onset
of hepatic
encephalopathy
At 5 days after
the onset of hepatic
encephalopathy
Patients for the formation
of the algorithm 1998–2003
(n = 371)
Accuracy 79.0 83.6
Sensitivity 77.6 82.6
Speciﬁcity 80.6 84.7
PPV 82.5 86.5
NPV 75.3 80.5
Patients for the validation
of the algorithm 2004–2007
(n = 160)
Accuracy 71.2 73.1
Sensitivity 75.0 63.6
Speciﬁcity 67.1 82.4
PPV 70.6 77.8
NPV 71.8 70.0
PPV positive predictive value, NPV negative predictive value
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123mortality rates were greater than 50% in patients for the
formation of the algorithm (Table 4a). In contrast, 53
patients (25.2%) were classiﬁed as category-1G, in which
the mortality rates were 25.0 and 29.4%, respectively, in
patients used for the formation and those used for the
validation of the algorithm.
The outcome at 5 days after the onset of hepatic
encephalopathy was assessed in 112 (53.1%) of the 211
patients who had received liver transplantation, because the
transplantation was done within 5 days after the onset of
hepatic encephalopathy in 99 patients (Table 4b). Conse-
quently, 75 (67.0%) of the 112 patients were classiﬁed as
category-2A, category-2B, category-2D, category-2E, or
category-2H for the formation of the algorithm, in which
categories the mortality rates were greater than 50%. Six-
teen patients (14.3%) were classiﬁed as category-2C for
validation of the algorithm, in which category the mortality
rate was greater than 90%, despite the fact that the mor-
tality in it was only 16.1% in the patients used for for-
mation of the algorithm.
Discussion
In the present study, we established a predictive model to
determine the outcome of patients with ALF through
decision tree analysis, one of the data-mining methods.
Data-mining has been applied to analysis in ﬁelds such as
business intelligence, marketing, banking and ﬁnance,
customer relationship management, and engineering, as
well as various areas of science, including medicine. In
clinical medicine, data-mining techniques are used to
construct a predictive model, which supports clinical
decisions for researchers as well as practitioners [17]. A
decision tree algorithm is one of the most popular data-
mining techniques, constructed through recursive data
partitioning, where the data are split according to the val-
ues of a selected attribute in iteration. Decision trees have
already been applied to the ﬁeld of hepatology; for exam-
ple, to analyze the characteristic features of hepatocellular
carcinoma [18–20], and to evaluate the therapeutic efﬁcacy
of pegylated-interferon and ribavirin for patients with
chronic hepatitis due to HCV infection [21, 22].
In the present study, algorithms of two types were
established; an algorithm for use at the onset of hepatic
encephalopathy and one for use 5 days later, because, in
Japan, conservative medical care including artiﬁcial liver
support is generally performed in most patients, including
those receiving liver transplantation, following the onset of
hepatic encephalopathy. In fact, as shown in Table 1c,
plasma exchange and hemodiaﬁltration were carried out in
more than 90 and 70%, respectively, of patients with ALF.
Thus, the outcome of the patients could be evaluated
5 days after the onset of hepatic encephalopathy in 53% of
patients receiving liver transplantation (Table 4). The data
sets obtained from ALF patients seen between 1998 and
Table 4 The numbers of deaths
and the mortality rates of
patients in each category
classiﬁed through decision tree
analysis: comparison among
patients used for the formation
of the algorithm, those used for
the validation of the algorithm,
and those who received liver
transplantation
Categories classiﬁed
through decision tree
analysis
Mortality rates of patients
% (number of patients)
Number of patients
Patients for algorithm
formation 1998–2003
(n = 371)
Patients for algorithm
validation 2004–2007
(n = 160)
Patients receiving
liver transplantation
1998–2007 (n = 211)
(a) The algorithm for the patients at the onset of hepatic encephalopathy
1A 89.0 (81/91) 83.9 (26/31) 95
1B 79.6 (39/49) 50.0 (16/32) 34
1C 22.6 (7/31) 37.5 (3/8) 10
1D 66.7 (20/30) 83.3 (10/12) 8
1E 30.8 (4/13) 18.2 (2/11) 7
1F 88.2 (15/17) 80.0 (8/10) 4
1G 25.0 (35/140) 30.2 (16/53) 53
(b) The algorithm for the patients at 5 days after the onset of hepatic encephalopathy
2A 93.1 (81/87) 86.4 (19/22) 19
2B 80.3 (53/66) 71.4 (15/21) 36
2C 16.1 (5/31) 91.7 (11/12) 16
2D 100.0 (8/8) – (0/0) 0
2E 75.8 (25/33) 72.7 (8/11) 18
2F 11.0 (12/108) 17.3 (9/52) 20
2G 29.6 (8/27) 25.0 (4/16) 1
2H 90.0 (9/10) – (0/0) 2
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1232003 were used for the formation of the algorithms and
those from the patients seen between 2004 and 2007 for
their validation, because the outcomes of the patients seen
in the two periods were almost equivalent, although there
were some differences between the two periods in the
frequencies of the therapeutic procedures undertaken
(Table 1c, d).
According to the established decision tree algorithms,
the patients with ALF were classiﬁed into 7 categories
through 6 items at the onset of hepatic encephalopathy and
into 8 categories through 7 items at 5 days after the onset
of hepatic encephalopathy. Serum bilirubin concentration
was selected as the ﬁrst split item in the former algorithm,
and the patients were further classiﬁed based on peripheral
blood platelet counts, age, presence or absence of ascites,
and the etiology of liver injuries. In contrast, the pro-
thrombin time at 5 days after the onset of encephalopathy
was the ﬁrst split item in the latter algorithm, and the
patients were then classiﬁed based on the serum bilirubin
concentration and presence or absence of cerebral edema,
liver atrophy, and cardiac and renal failure at the onset of
encephalopathy or 5 days later. The interval between the
onset of disease symptoms and hepatic encephalopathy has
been considered to be one of the most important factors to
determine the prognosis of ALF patients [4], and this factor
was selected as a parameter in the previous guidelines [5].
The prothrombin time and the ratio of the direct-to-total
bilirubin concentration at the onset of hepatic encepha-
lopathy were previously selected as parameters as well [5].
However, these factors were not chosen as items respon-
sible for the prognosis of ALF patients in our novel model
established through decision tree analysis. These decisions
are in line with ﬁndings in our previous report [7], in which
ALF patients could be classiﬁed into three clusters inde-
pendent of the interval between the onset of disease
symptoms and the onset of hepatic encephalopathy, and the
prognosis of the patients differed markedly among the
clusters. Moreover, among 7 items in the algorithms at
5 days after the onset of hepatic encephalopathy, the extent
of cerebral edema, renal failure, and heart failure may vary
depending on the therapeutic devices used, especially
regarding methods for artiﬁcial liver support (ALS) [23–
25]. High-ﬂow continuous hemodiaﬁltration (CHDF) and
on-line hemodiaﬁltration (HDF) are much more effective
than conventional HDF and CHDF [26, 27]. In the present
study, most of the patients received conventional CHDF
and HDF (data not shown), and such therapeutic devices
were not selected as factors affecting the prognoses of the
patients.
Certain characteristic features in both our algorithms are
deserving of inclusion in the algorithms. First, the cate-
gories can be divided into 2 types depending on their
mortality rates; the mortality rates in patients used for the
formation of the model were greater than 66.7% in 4 cat-
egories in both algorithms, while they were less than 33.3%
in the remaining 3 and 4 categories, respectively, in the
algorithm used at the onset of hepatic encephalopathy and
that used 5 days later. Secondly, 341 of the 371 patients
used for the establishment of decision trees (91.9%) were
classiﬁed into 4 major categories, in which the number of
patients belonging to each category was greater than 30 in
the algorithm at the onset of hepatic encephalopathy. Also,
325 patients (87.6%) were classiﬁed into 5 major catego-
ries in the algorithm at 5 days after the onset of hepatic
encephalopathy. Considering these characteristic features
of both algorithms, the novel model constructed through
the decision tree analysis seems to be useful for the pre-
diction of the outcome of patients with ALF, because the
ﬁrst characteristic above allowed the analysis to achieve
high accuracy rates when the outcomes of the patients were
predicted qualitatively as ‘‘death’’ or ‘‘survival’’. In con-
trast, the second characteristic may enable us to obtain
stable results for prediction even after the validation. In
fact, as shown in Table 3, the predictive accuracies of both
algorithms were high; 79.0 and 83.6%, respectively, in the
algorithm at the onset of hepatic encephalopathy and that at
5 days later, when the outcome of patients belonging to the
categories with mortality rates greater than 50% was pre-
dicted as ‘‘death’’. Moreover, the sensitivity, speciﬁcity,
PPV, and NPV values were greater than 75% in the algo-
rithm at the onset of hepatic encephalopathy, and greater
than 80% in the algorithm at 5 days later. Also, the mor-
tality rates in patients used for the algorithm formation
were similar to those in the patients used for the validation
in each category, except for category-2C. As a result, the
predictive accuracies were also high in patients used for the
validation algorithm; 71.2 and 73.1%, respectively, in
the algorithm at the onset of hepatic encephalopathy and
that at 5 days later, when the outcome of patients was
assessed qualitatively. Thus, it is concluded that the present
model, consisting of 2 algorithms, may be useful to predict
the outcome of ALF patients both quantitatively and
qualitatively. Clinicians can obtain the predictive mortality
rates of the patients depending on the categories to which
the patients belong, and they can also predict the outcome
as ‘‘death’’ or ‘‘survival’’ with satisfactory accuracies.
However, there are several weak points in both algo-
rithms to predict the outcome of the ALF patient. Although
the reproducibility of the algorithm at the onset of hepatic
encephalopathy was generally good in each category, a
29.6% difference in mortality rates was found between the
formation and validation data sets in category-1B. Also,
there was a 75.6% difference between the two data sets in
category-2C. Moreover, the validation could not be done in
categories-2D and -2H, because no patients were classiﬁed
in these categories in the validation groups, and a similar
J Gastroenterol (2012) 47:664–677 675
123situation was found in the analysis of patients who had
received liver transplantation. The signiﬁcance of such
minor terminal nodes (leaves) constructed with small
numbers of patients should be further validated in patients
enrolled in the nationwide survey since 2008.
Liver transplantation was performed in 221 (21.6%) of
the 1,022 patients enrolled in the study. These patients
were excluded from the subjects used for the formation and
validation of the decision tree algorithms. However, we
evaluated the possible outcomes of these patients using the
established algorithms. To our surprise, as shown in
Table 4, 33% of the transplanted patients were classiﬁed
into the categories showing a predictive mortality rate of
less than 50% both at the onset of hepatic encephalopathy
and at 5 days later. We note particularly that there existed
53 of 211 transplanted patients (25.1%) belonging to cat-
egory-1G, with predictive mortality rates of 25.0 and
29.0%, respectively, in patients used for the formation and
those used for the validation of the algorithms. Thus, the
clinical features of transplanted patients should, in the
future, be evaluated retrospectively with reference to
peripheral blood platelet counts and the etiology of liver
injury, as well as serum bilirubin concentration, the items
responsible for classiﬁcation as category-1G. Also, it
should be noted that 16 of 112 patients (14.3%) were
classiﬁed as category-2C at 5 days after the onset of
hepatic encephalopathy. The signiﬁcance of category-2C,
characterized by items such as cerebral edema, liver atro-
phy, and cardiac failure, should be investigated further.
In Europe and the United State, the indications for liver
transplantation in patients with ALF have been evaluated
based on the guidelines proposed by O’Grady et al. [28], in
which the prognosis was estimated differently in patients
with liver failure due to acetaminophen intoxication and
those with liver failure caused by viral hepatitis and drug
allergy-induced liver injury. In the former category of
patients, the prognosis was estimated based on three
parameters: arterial blood pH, peak prothrombin time, and
the serum creatinine level. In contrast, in the latter category
of patients, the prognosis was determined based on 5
parameters: etiology of the disease, age of the patient, the
duration of jaundice before the onset of hepatic encepha-
lopathy, peak prothrombin time, and the serum bilirubin
level. Thus, the usefulness of our novel model based on the
decision tree analysis should also be evaluated in ALF
patients in Europe and the United States, especially in
those with acute liver failure due to viral hepatitis and drug
allergy-induced liver injury, in comparison with the
guidelines proposed by O’Grady et al. [28]. However, it
should be kept in mind that the purpose of our model is to
predict the possible mortality rates of ALF patients, but not
to determine the indication for liver transplantation auto-
matically. In our model, cerebral edema and cardiac
failure, which may disallow the patients from receiving
liver transplantation, are included as split items. Liver
transplantation cannot be performed for patients showing
high mortality rates due to complications caused by ALF
that correspond to items that are contra-indications for
surgical procedures.
In conclusion, we have developed a novel model con-
sisting of two algorithms for predicting the outcome of
ALF patients at the onset of hepatic encephalopathy and at
5 days later, through decision tree analysis. This system
may be useful to determine the indication for liver trans-
plantation, because the mortality rates can be estimated by
the algorithms with high accuracy rates, which were sim-
ilarly high both before and after validation.
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